Investigation of the ecotoxicologic effect of pesticide industry wastewater on the pancreas and liver of rats

In this study, when the raw wastewater, which resulted from the manufacturing of 2,4- dichlorophenoxyacetic acid (2,4-D) dimethylamine salt and 2,4-D acid isooctylester herbicides in the factory, was discharged to the ecosystem without treatment, its ecotoxic effect on the pancreas and liver of rats was investigated. In this research, 16 Wistar Albino race male rats were grouped into two (Group 1- control, n = 8; Group 2- wastewater, n = 8) and were then used. The rats in Group 1 were fed by standard feed, while rats in Group 2 were fed by a diet including 200 mg/kg/day factory composite raw wastewater for 16 weeks, and dissection was carried out for all of them. In the research, it was determined that the body, liver and pancreas weights of rats were decreased when compared to the control group; however, there was no significant statistical difference (P > 0.05) between the twogroups. In the histopathological investigation, on the other hand, it was determined that atypical cell focuses (ACF) (neoplastic variations) were observed in the liver and pancreas of rats in Group 2 and the quantitative analysis of the ACF was performed. In the livers of rats in Group 2, dilation in sinusoids close to the vein centralis and hydropic degeneration in parenchyma were observed when compared to the control group. Since there is a possibility that the neoplastic variations caused by this wastewater could be transformed into adenoma or carcinoma during long-term treatment, it also seems possible that it could be carcinogenic.Key words: 2,4-Dichlorophenoxyacetic acid (2,4-D), herbicide, wastewater, atypical cell focuses, pancreas and liver, ecotoxic effect

Experimental ancilla-assisted qubit transmission against correlated noise using quantum parity checking

We report the experimental demonstration of a transmission scheme of photonic qubits over unstabilized optical fibers, which has the plug-and-play feature as well as the ability to transmit any state of a qubit, regardless of whether it is known, unknown, or entangled to other systems. A high fidelity to the noiseless quantum channel was achieved by adding an ancilla photon after the signal photon within the correlation time of the fiber noise and by performing quantum parity checking. Simplicity, maintenance-free feature and robustness against path-length mismatches among the nodes make our scheme suitable for multi-user quantum communication networks.Comment: 8 pages, 4 figures; published in New J. Phys. and selected in IOP Selec

Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanoma-A Real World Single-Center Analysis.

Approved adjuvant treatment options for stage III melanoma are the immune checkpoint inhibitors (ICI) pembrolizumab and nivolumab, and in presence of a BRAF V600E/K mutation additionally dabrafenib in combination with trametinib (BRAFi/MEKi). This study aims to describe prescription patterns and recurrence and toxicity rates of adjuvant-treated melanoma patients from the Cancer Center of the University Hospital Bern, Switzerland. One hundred and nine patients with an indication for adjuvant treatment were identified. Five (4.6%) had contraindications and, as such, were not proposed any adjuvant treatment, while 10 patients (9.2%) declined treatment. BRAF status was known for 91 (83.5%) patients. Of 40 (36.7%) patients with BRAF V600E/K melanoma, pembrolizumab was prescribed to 18 (45.0%), nivolumab to 16 (40.0%), and dabrafenib/trametinib to three (7.5%) patients. Grade 3-4 toxicity was reported in 18.9% and 16.7% of all the patients treated with pembrolizumab and nivolumab, respectively. No toxicities were observed for dabrafenib/trametinib. Thirty-eight percent of the patients treated with pembrolizumab and 40.0% of those treated with nivolumab relapsed. No relapses were reported for dabrafenib/trametinib. Prescription patterns indicate a clear preference for adjuvant ICI treatment

Peroxidase-like activity of hemoglobin-based hybrid materials against different substrates and their enhanced application for H2O2 detection

ABSTRACT. Organic-inorganic hybrid nanoflowers method with unique properties are preferred than conventional immobilization methods for the past decade. Hereemoglobin-based hybrid material (HbNFs@Cu) was synthesized under different experimental conditions (pH 5.0-9.0 and 0.01-0.50 mgmL-1 of hemoglobin) obtaining a material size of 9-10 µm. The encapsulation percentage and weight yield of HbNFs@Cu were determined as 100% and 6.7%, respectively. The peroxidase-like activities of the material against different substrates (ABTS and Guaiacol) were compared to free hemoglobin. The HbNFs@Cu hybrid structure exhibited Vmax of 3.6995 EU/mg and a Michaelis-Menten constant (KM) of 0.1357 mM/mL. The HbNFs@Cu hybrid material was then used to catalyze the oxidation of a peroxidase substrate ABTS to the pigmented product, which provided a colorimetric and spectrophotometric detection of H2O2. The linear operating range, detectable colorimetrically as H2O2 sensor, is 0.005-0.0042 mM, while the linear operating range, detectable spectrometically, is 0.003-0.0042 mM. The limits of detection of colorimetric and spectrophotometric sensors were 0.005 mM and 0.003 mM, respectively. Collectively, these results showed that HbNFs@Cu can be used as colorimetric biosensor for H2O2 in potential applications such as pharmaceutical food, biomedical, environmental, and industrial.                     KEY WORDS: Hydrogen peroxide, Hemoglobin, Hybrid Material, Colorimetric assay   Bull. Chem. Soc. Ethiop. 2021, 35(3), 537-550.  DOI: https://dx.doi.org/10.4314/bcse.v35i3.

The Role of Immune Checkpoint Inhibitors in Metastatic Pancreatic Cancer: Current State and Outlook.

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest tumors, characterized by its aggressive tumor biology and poor prognosis. While immune checkpoint inhibitors (ICIs) play a major part in the treatment algorithm of various solid tumors, there is still no evidence of clinical benefit from ICI in patients with metastatic PDAC (mPDAC). This might be due to several reasons, such as the inherent low immunogenicity of pancreatic cancer, the dense stroma-rich tumor microenvironment that precludes an efficient migration of antitumoral effector T cells to the cancer cells, and the increased proportion of immunosuppressive immune cells, such as regulatory T cells (Tregs), cancer-associated fibroblasts (CAFs), and myeloid-derived suppressor cells (MDSCs), facilitating tumor growth and invasion. In this review, we provide an overview of the current state of ICIs in mPDAC, report on the biological rationale to implement ICIs into the treatment strategy of pancreatic cancer, and discuss preclinical studies and clinical trials in this field. Additionally, we shed light on the challenges of implementing ICIs into the treatment strategy of PDAC and discuss potential future directions

Toxicity, disease management and outcome of treatment with immune checkpoint inhibitors by sex in patients with cancer and preexisting autoimmune disease.

Female sex is associated with a higher risk for autoimmune diseases (ADs) and immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs). While the safety of ICIs in AD cohorts has been reported, sex-segregated data on patient characteristics and outcomes are lacking. In the present study, the disease and treatment characteristics of 51 patients with cancer and preexisting AD (PAD) treated with ICIs at Bern University Hospital Cancer Center (Bern, Switzerland) between January 2017 and June 2021 were analyzed by sex. Rheumatic (n=12/27, 44.4%) and endocrine (n=11/24, 45.8%) PADs were most common among male and female patients, respectively. At the time of ICI initiation, 29.6% (n=8/27) of male and 20.8% (n=5/24) of female patients received immunosuppression for their PAD. Female patients were more likely to experience an irAE (58.3 vs. 48.1%), and less likely to encounter an exacerbation of their PAD (38.5 vs. 14.3%) compared with male patients. Multiple-site irAEs (46.2 vs. 21.4%), implication of an organ specialist for irAEs (100.0 vs. 57.1%) and use of additional immunosuppressive drugs (38.4 vs. 7.7%) were more common in male patients. IrAEs were resolved and ICIs were discontinued in 69.2% (n=9/13) and 71.4% (n=10/14) of the total male and female patients, respectively. Median progression-free survival was higher in male than female patients with irAEs (19.9 vs. 10.7 months) and without irAEs (4.4 vs. 1.8 months). The median overall survival time was higher in male than female patients with irAEs (not estimable vs. 22.5 months) and without irAEs (10.1 vs. 7.4 months). Taken together, these results suggested that sex-related differences existed regarding the clinical presentation of irAEs and treatment outcome

Quantum random number generation using an on-chip nanowire plasmonic waveguide

Quantum random number generators employ the inherent randomness of quantum mechanics to generate truly unpredictable random numbers, which are essential in cryptographic applications. While a great variety of quantum random number generators have been realised using photonics, few exploit the high-field confinement offered by plasmonics, which enables device footprints an order of magnitude smaller in size. Here we integrate an on-chip nanowire plasmonic waveguide into an optical time-of-arrival based quantum random number generation setup. Despite loss, we achieve a random number generation rate of 14.4 Mbits/s using low light intensity, with the generated bits passing industry standard tests without post-processing. By increasing the light intensity, we were then able to increase the generation rate to 41.4 Mbits/s, with the resulting bits only requiring a shuffle to pass all tests. This is an order of magnitude increase in the generation rate and decrease in the device size compared to previous work. Our experiment demonstrates the successful integration of an on-chip nanoscale plasmonic component into a quantum random number generation setup. This may lead to new opportunities in compact and scalable quantum random number generation.Comment: 10 pages, 3 figures, appendi

Next generation of life cycle related benchmarks for low carbon residential buildings in Germany

Germany\u27s national climate targets are in line with the Paris Climate Agreement and set the ambitious goal of becoming net zero emissions by 2045. The construction and real estate sector play an important role for sustainable development. In a cross-sectoral approach operational and embodied emissions of buildings account for 40% of GHG emissions in Germany. In order to contribute to climate protection, it is necessary to both pursue a strategy for decarbonizing the national building stock and to develop benchmarks for assessing greenhouse gas emissions in the life cycle of individual buildings. In Germany, benchmarks are used in sustainability assessment systems for more than 10 years to assess primary energy non-renewable (PENRT) and global warming potential (GWP) in the life cycle of buildings. Therefore, these need to be regularly reviewed and further developed in order to (1) adapt them to more ambitious reduction targets, (2) consider the current database, (3) include the state of standardization, and (4) follow the state of scientific discussion on methodological issues. This paper identifies new benchmarks for PENRT and GWP and shows the scale of current levels of performance. These can form the basis for funding programs and contribute to the discussion on the introduction of binding legal requirements

Sex and gender differences in anticancer treatment toxicity - a call for revisiting drug dosing in oncology.

The practice of oncology has dramatically changed in the last decade with the introduction of molecular tumor profiling into routine tumor diagnostics and the extraordinary progress in immunotherapies. However, there remains an unmet need to explore personalized dosing strategies that take into account the patient's sex to optimize the balance between efficacy and toxicity for each individual patient. In this mini-review, we summarize the evidence on sex differences in toxicity of anticancer therapies and present data on dose reduction and dose discontinuation rates for selected chemotherapies and targeted therapies. Finally, we propose the investigation of body composition (specifically fat free muscle mass) as a viable approach for personalized treatment dosage